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Summary The activities of 3-phosphoglycerate dehydrogenase, an enzyme of serine biosynthesis, and serine
hydroxymethyltransferase, serine dehydratase and serine aminotransferase, which are competing enzymes of
serine utilization, were assayed in human colon carcinomas from patients and in transplantable rat sarcomas.
Serine dehydratase and serine aminotransferase activities were absent, whereas 3-phosphoglycerate
dehydrogenase and serine hydroxymethyltransferase activities were markedly increased in both tumour types.
Serine hydroxymethyltransferase catalyses the formation of glycine and methylene tetrahydrofolate which are
important precursors for nucleotide biosynthesis. The observed enzymic imbalance in these tumours ensures
that an increased capacity for the synthesis of serine is coupled to its utilisation for nucleotide biosynthesis as
a part of the biochemical commitment to cellular replication in cancer cells. That this pattern is found in
sarcomas and carcinomas, and in tumours of human and rodent origin, signifies its universal importance for
the biochemistry of the cancer cell and singles it out as a potential target site for anti-cancer chemotherapy.
Although serine is a nutritionally dispensable amino acid in
animals, it has an essential role in providing the major
intracellular source of one-carbon tetrahydrofolate adducts
which donate carbon for the synthesis de novo of purine and
pyrimidine nucleotide bases. During cellular proliferation the
demands for increased nucleotide biosynthesis for DNA
replication will have to be matched by a corresponding
increase in serine utilisation for nucleotide precursor
formation. Indeed, recent studies have shown enhanced 14C-
serine incorporation into nucleotides during the transition of
cells from the quiescent to proliferative growth phases in
mitogenically-stimulated lymphocytes (Eichler et al., 1981;
Rowe et al., 1985) and in hepatoma cells (Snell et al., 1987)
in culture. Serine hydroxymethyltransferase promotes serine
utilization for this purpose, and its activity increases in
parallel with serine incorporation into nucleotides in the
above situations (Eichler et al., 1981; Thorndike et al., 1979;
Snell et al., 1987). The reaction involves not only the
formation of methylene tetrahydrofolate which acts as a
direct carbon source for thymidylate synthesis and an
indirect carbon source (via conversion to other tetrahydro-
folate cofactors) for purine synthesis, but also the formation
of glycine which acts as a carbon and nitrogen source for
purine synthesis. Thus, serine participates in both the
thymidylate synthesis cycle and in purine biosynthesis
(Figure 1). In view of the attention given the other com-
ponent enzymes of the thymidylate synthesis cycle as targets
for anti-cancer chemotherapy, it is perhaps surprising that
serine hydroxymethyltransferase has not been more inten-
sively studied in tumours. In recent studies of transplantable
rat tumours (mainly hepatomas) it was shown that serine
hydroxymethyltransferase activity was selectively retained or
increased whereas competing enzymes of serine utilization,
serine dehydratase and serine aminotransferase, were deleted
(Snell, 1985; Snell & Weber, 1986). This reprogamming of
serine metabolism in tumours ensures that serine is
specifically channelled into the provision of nucleotide
precursors in cancer cells in keeping with the general
biochemical strategy of such cells which subserves their
commitment to proliferation (Snell, 1984; Weber, 1983).
The hypothesis was advanced that serine utilization for
nucleotide synthesis in cancer cells is coupled to an increased
capacity for the intracellular synthesis de novo of serine from
glycolytic precursors to ensure the autonomy of these cells
in relation to growth potential (Snell, 1984). The key enzyme
of the serine biosynthetic pathway, 3-phosphoglycerate
dehydrogenase, was shown to be increased in a series of
transplantable Morris hepatomas in proportionality with
tumour growth rate (Davis et al., 1970; Snell & Weber,
1986). It would seem essential in order to test the validity of
the above hypothesis and to further substantiate the role of
serine metabolism in cancer cells, to extend the studies to
other cancers. In particular, it is important to establish
whether the reorientation of serine metabolism identified in
carcinomas can be extended to sarcomas, and also whether
the pattern observed in rodent tumours is applicable to
human neoplasms. These aims were addressed in the present
study by investigating the enzymes of serine metabolism in a
transplantable rat sarcoma model and in human colon
carcinoma.
Materials and methods
Animals and tumours
For these studies, a methylcholanthrene-induced sarcoma
line carried in male Fischer (F344) rats (Charles River
Laboratories, Portage, MI, USA) and skeletal muscle from
control, normal rats of the same sex, strain, age and weight
were used. This tumour is characterised as a rhabdomyo-
sarcoma; the induction, maintenance and biological
behaviour have been described elsewhere (Popp et al., 1981).
It is a moderately rapidly growing neoplasm comparable in
growth rate to the transplantable hepatoma 3924A
previously investigated in this laboratory in relation to
enzymes of serine metabolism (Snell & Weber, 1986). The
sarcoma reaches a diameter of 1.5cm in about 14 days, with
death occurring 30-34 days after inoculation. Animals were
inoculated on the flank by s.c. injection of - 106 viable
tumour cells and were housed individually in air-conditioned
rooms with illumination from 06.00-19.00h daily. Food and
water were available ad libitum. The tumour was used for
enzyme assays at 12-18 days after inoculation, at which time
it was free of necrosis. Rats were killed, without the use of
anaesthetic, between 09.00 and 10.00h. Tumour tissue was
rapidly excised and dissected to provide samples free of non-
tumorous or haemorrhagic areas.
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Clinical material
In this series of 4 cases (male subjects aged between 64 and
76 years of age), the colon adenocarcinomas and normal
colon tissue were obtained at operations from patients
undergoing surgical resection at the hospitals of the Indiana
University School of Medicine. Histological grading of the 4
specimens determined that 2 were moderately differentiated
and 2 were poorly differentiated. The surgical samples were
from the following sites: the splenic flexure, the ascending
colon, the sigmoid and the rectum. Because of the small
number of cases, a statistical evaluation did not reveal
significant differences between the enzyme activities in
different histological grades of neoplasms, nor were enzymic
differences between different surgical sites of the tumours
apparent. For this reason, the data of the enzyme assays
from all neoplasms were combined in this study.
As soon as tissues were removed from the patient samples
were taken for pathology; the colon specimens were placed
in beakers embedded in ice and within 30min were
transferred to this laboratory. The tissues were processed
immediately for analysis by stretching the colon over a glass
plate standing on crushed ice. The normal colon mucosa
from clearly uninvolved areas of the specimen was carefully
scraped off, and the tumour tissue was cut out with scissors,
separated from non-tumorous, necrotic or haemorrhagic
areas, and placed in ice-cold beakers standing in crushed ice.
For each surgical specimen, different parts of the tumour
were sampled to provide multiple assays from potentially
different populations of tumour cells. The mucosa of the
uninvolved areas of the colon (confirmed as histologically
normal in each case) of the same patient served as the
control for the carcinoma. Concurrently with preparation of
the human samples, livers of normal male Wistar rats of
200g body weight were processed. Comparison of the rat
liver enzyme activities with previous results (Snell & Weber,
1986) revealed no significant differences and provided an
internal control for the enzyme determinations.
Enzyme assays
Tissue homogenates were prepared and the cytosol fraction
was obtained as described previously (Snell & Weber, 1986).
Serine hydroxymethyltransferase and serine aminotransferase
were assayed in unfractionated whole homogenates and 3-
phosphoglycerate dehydrogenase and serine dehydratase
were measured in cytosol fractions as described by Snell and
Weber (1986). It was confirmed in the present study that the
assay conditions for the enzymes in the human colon and rat
sarcoma systems were optimal and that all activities were
measured under linear kinetic conditions. Enzyme activities
are expressed as nmol of product formed/h per mg of
homogenate or cytosolic protein as appropriate. The mean
values and SEM of the tumour activities were compared
with those of the corresponding control tissue using the
Students t test for small samples.
Results and discussion
Enzyme activities in rat sarcoma
The activities of enzymes of serine metabolism in the rat
sarcoma are shown in Table I. The activity of 3-
phosphoglycerate dehydrogenase, the initiating enzyme of the
serine biosynthetic pathway, is elevated 32-fold compared to
that in normal skeletal muscle. The absolute value in skeletal
muscle is similar to that previously measured in the rat heart
and other tissues with a low capacity for cell renewal (Snell
& Weber, 1986). The marked increase found in tumour
tissue compared to control tissue confirms the pattern
previously shown for rat liver carcinoma (Snell & Weber,
1986). This enzyme activity has not previously been
measured in rhabdomyosarcoma; however, phosphoserine
phosphatase, the final enzyme in the serine biosynthetic
pathway, exhibited high activity in a range of rat tumours
(primary and transplanted) including in a transplantable
osteogenic sarcoma (Knox et al., 1969). The general pattern,
that the enzymic capacity for serine biosynthesis is increased
in carcinomas (Snell, 1984,1985), is substantiated here for
sarcomas.
Of the enzymes of serine utilization assayed in the present
work, serine dehydratase and serine aminotransferase are
absent from both control skeletal muscle and the sarcoma
(Table I). On the other hand, serine hydroxymethyltrans-
ferase, a competing enzyme for serine utilization, is increased
6-fold in the sarcoma. This enzymic imbalance will serve to
preferentially channel serine into the provision of nucleotide
precursors. It is noteworthy that in liver where serine
dehydratase and serine aminotransferase activities are
present in substantial amounts, the preferential reorientation
of serine utilization for nucleotide precursor formation in the
corresponding tumour is achieved by a deletion of these
competing enzymes whilst retaining a proportion of serine
hydroxymethyltransferase activity (Snell, 1984, 1985; Snell &
Weber, 1986). In other tissues, which do not possess serine
dehydratase and serine aminotransferase activities, this
preferential utilization of increased serine availability can be
achieved only by increasing substantially the activity of
serine hydroxymethyltransferase in the tumours (present
work; Snell, 1985). In so far as the proposed enzymic
reorientation of serine metabolism allows for the coupling of
serine synthesis to its utilization for nucleotide precursor
formation for cellular replication in cancer cells, this pattern
conforms to that observed previously in the rat sarcoma in
this laboratory (Weber et al., 1983). This earlier study
established that the enzymic programme for pyrimidine,
purine and carbohydrate metabolism exhibited by the
sarcoma accounted for the observed expansion of the intra-
cellular ribonucleotide pools and subserved a formidable
biochemical capacity for cellular replication.
Enzyme activities in human colon carcinoma
The patterns of serine metabolism in tumours established in
our previous studies (Snell, 1984,1985; Snell & Weber, 1986)
have all employed transplantable rat tumours as model
systems. However, if the patterns are to have significance in
terms of human neoplasia, and particularly in relation to the
development of strategies for enzyme-targeted anti-cancer
drug therapy, then they must also be demonstrated in human
cancers. The activities of enzymes of serine metabolism in
human colon carcinoma are shown in Table I. The activity
of 3-phosphoglycerate dehydrogenase is elevated 10-fold, and
Table I Enzymes of serine metabolism in rat sarcoma and in
human colon carcinoma
Activity: nmolh 1 mg1 protein
(% ofcontrol values)
Control Human Human
rat skeletal Rat control colon
musclea sarcoma' colon mucosab carcinomab
Phosphoglycerate 30.5+2.8 984+38' 233 +25 2404+ 173c
dehydrogenase (100) (3226) (100) (1032)
Serine hydroxy- 11.4+0.7 70.4+2.1c 80.9+7.5 378+10I
methyltransferase (100) (618) (100) (467)
Serine <5 <5 <5 <5
dehydratase
Serine <5 <5 <5 <5
aminotransferase
aMean +s.e. of 6-8 measurements on muscles and sarcomas from
separate animals; bMean+s.e. of 10 measurements on normal colon
mucosas and colon carcinomas from 4 different patients;
cStatistically different from control values at P<0.001. Tissue
homogenates were made and enzyme activities assayed as described
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that of serine hydroxymethyltransferase nearly 5-fold, in the
tumour compared to control colon mucosa. In common with
the rat sarcoma (see above) and other rat tumours, the
competing enzymes of serine utilization, serine dehydratase
and serine aminotransferase, are absent from the colon
carcinoma, as indeed they are from control human colon
mucosa.
In rat tissues a close proportionality between 3-
phosphoglycerate dehydrogenase activity and the overall
capacity for serine biosynthesis has been demonstrated
(Davis et al., 1970). If a similar correlation can be assumed
for human tissues, then the present results show an enhanced
capacity for serine biosynthesis in human colon carcinoma,
which is coupled to its increased utilization by serine
hydroxymethyltransferase. Serine hydroxymethyltransferase
has also been shown to be elevated in human lymphocytic
and granulocytic leukaemias compared to normal lympho-
cytes and granulocytes respectively (Thorndike et al., 1979).
Previous studies of the enzymology of pyrimidine, purine
and carbohydrate metabolism in human colon carcinoma
have demonstrated increased capacities of the de novo and
salvage pathways of nucleotide biosynthesis (Weber et al.,
1980; Denton et al., 1982; Natsumeda et al., 1985). The
present findings for serine metabolism indicate that it
contributes to this biochemical commitment to proliferation
of the cancer cells.
General conclusions and implicationsfor anti-cancer therapy
The present data are important in demonstrating that the
reorientation of serine metabolism previously identified in rat
carcinomas (Snell, 1984, 1985; Snell & Weber, 1986) is also
present in a rat sarcoma model and in human colon adeno-
carcinomas. This considerably reinforces the generality of
the hypothesis (Snell, 1984) that the increased capacity for
serine synthesis in cancer cells is coupled to its preferential
utilization for the provision of nucleotide precursors. In
hepatoma cells in different phases of growth in culture it has
been established that the changing activity of serine hydroxy-
methyltransferase correlates with the flux of 14C-serine into
purine and pyrimidine bases of cellular nucleic acids (Snell
et al., 1987). The importance of serine metabolism for the
replication of cancer cells is emphasised by their increased
capacity to synthesize serine de novo rather than simply
relying on the uptake of this amino acid from the extra-
cellular fluid.
This work has implications for new strategies for anti-
cancer chemotherapy and, in this regard, it is important that
the characteristic reorientation of serine metabolism which
has been identified in rodent neoplasias has been confirmed
in human neoplasia. In view of the preferential utilization of
serine in cancer cells for the provision of one-carbon
cofactors and of glycine for the pathways of de novo
nucleotide biosynthesis, serine hydroxymethyltransferase can
be considered a prime target for the design of enzyme-
directed chemotherapy. There is a precedent for the use of
amino acid utilizing enzymes as targets for anti-metabolite
based anti-cancer therapies in the development of the
glutamine analogue acivicin (Weber, 1983; Weber et al.,
1984) which is presently in clinical trials.
Serine hydroxymethyltransferase is one of the trio of
enzymes which participate in the thymidylate synthesis cycle
(Figure 1), and it is noteworthy that each of the other two
enzymes of the cycle has proved an important target for
established clinically-useful chemotherapeutic agents.
Thymidylate synthase is the target for 5-fluorouracil, and
dihydrofolate reductase is the target for methotrexate. The
need for a further target in this metabolic area is indicated
by the development of resistance to these drugs in human
tumour cell populations. Moreover, serine hydroxymethyl-
transferase has the advantage that its inhibition not only
interferes with the synthesis of the pyrimidine, thymidylate,
but also with the formation of glycine as a purine base
precursor (Figure 1). The inhibition of DNA synthesis would
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Figure 1 The role of serine metabolism in DNA synthesis. The
enzymes involved are: TS, thymidylate synthase (EC 2.1.1.45);
DHFR, dihydrofolate reductase (EC 1.5.1.3); and SHMT, serine
hydroxymethltransferase (EC 2.1.2.2), in the thymidylate
synthesis cycle; and PGDH, 3-phosphoglycerate dehydrogenase
(EC 1.1.1.95), in the biosynthetic pathway leading from
glycolysis to serine formation.
involve the concurrent blocking of two parallel contributing
pathways and would result in a combination chemo-
therapeutic effect from a single inhibitory agent. Types of
inhibitors which might be usefully targeted to serine
hydroxymethyltransferase would include anti-folate ana-
logues or serine antimetabolites. Two features of the enzyme
mechanism could be exploited to achieve specificity of
inhibitory action: the involvement of pyridoxal phosphate as
an obligatory cofactor, and the ability of the enzyme to bind
certain D-amino acids. Vitamin B6 antimetabolites, such as
D-cycloserine or 4-vinylpyridoxal, have been shown to be
effective inhibitors of the enzyme in vivo (Bukin et al., 1979).
D-Fluoroalanine, an active site-directed suicide inhibitor of
the enzyme, has also been shown to be inhibitory in vitro
(Wang et al., 1981). A potentially valuable approach would
be to combine these features in a single Schiff s base-type of
inhibitory agent. Finally, it should be noted that it is
unlikely that an inhibitor of serine hydroxymethyltransferase
alone would be clinically useful in obtaining full remission in
the treatment of tumours. In the case of human colon
carcinoma, for example, it has been shown that the presence
of active pyrimidine and purine salvage pathways would
mitigate any actions based solely on the use of de novo
nucleotide pathways antimetabolites (Weber, 1983;
Natsumeda et al., 1985). Since the biochemical commitment
to proliferation of human cancers, as in other neoplasias,
involves increased activities of both de novo and salvage
pathways of nucleotide biosynthesis, the most rational
approach and that likely to be of most clinical benefit is a
combination chemotherapy involving antimetabolites and
inhibitors of salvage nucleoside transport as discussed
elsewhere (Weber, 1983; Natsumeda et al., 1985). The results
in this paper suggest that the development of inhibitors of
serine hydroxymethyltransferase as the antimetabolite
component of a combination therapeutic regimen appears to
be a strategy worthy of further investigation.
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